Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses

Radiotherapy and Oncology

Volumn 59, Issue 2, 2001, Pages 203-212

  Pajonk, Frank ^a   McBride, William H ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute phase reactants; Gene regulation; Inflammatory mediators; Signal transduction; Transcription factors

Indexed keywords

CHYMOTRYPSIN; HEAT SHOCK PROTEIN 90; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN SUBUNIT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IONIZING RADIATION; LOW ENERGY RADIATION; PRIORITY JOURNAL; RADIATION DOSE;

CELLS, CULTURED; DNA-BINDING PROTEINS; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; NF-KAPPA B; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIATION, IONIZING;

EID: 0035337151     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(01)00311-5     Document Type: Article

References (50)

1. Adams J., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 8:(4):1998;333-338.
2. Anderson A., Woloschak G.E. Cellular proto-oncogene expression following exposure of mice to gamma rays. Radiat Res. 130:(3):1992;340-344.
3. Baeuerle P.A., Baltimore D. NF-kappa B: ten years after. Cell. 87:(1):1996;13-20.
4. Basu S., et al. The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage. Biochem Biophys Res Commun. 247:(1):1998;79-83.
5. Belich M.P., Trowsdale J. Proteasome and class I antigen processing and presentation. Mol Biol Rep. 21:(1):1995;53-56.
6. Bender K., et al. Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV. EMBO J. 17:(17):1998;5170-5181.
7. Brach M.A., et al. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest. 88:(2):1991;691-695.
8. Chiang C.-S., Hong J.-H., Stalder A., Sun J.-R.H., Withers H.R., McBride W.H. Delayed molecular responses to brain irradiation. Int J Radiat Biol. 72:(1):1997;45-53.
9. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:(1):1994;13-21.
10. Clesham G.J., et al. High adenoviral loads stimulate NF kappaB-dependent gene expression in human vascular smooth muscle cells. Gene Therapy. 5:(2):1998;174-180.
11. Dirkis W.G., MacLeod R.A., Drexier H.G. ECV 304 (endothelial) is really T24 (bladder carcinoma): cell line cross-contamination at source [letter]. In Vitro Cell Dev Biol Anim. 35:(10):1999;558-559.
12. Glas R., et al. A proteolytic system that compensates for loss of proteasome function. Nature. 392:(6676):1998;618-622.
13. Groettrup M., et al. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today. 17:(9):1996;429-435.
14. Gubits R.M., Geard C.R., Schiff P.B. Expression of immediate early genes after treatment of human astrocytoma cells with radiation and taxol. Int J Radiat Oncol Biol Phys. 27:(3):1993;637-642.
15. Hallahan D.E., et al. Radiation signaling mediated by Jun activation following dissociation from a cell type-specific repressor. J Biol Chem. 268:(7):1993;4903-4907.
16. Hallahan D.E., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1:(8):1995;786-791.
17. Hallahan D.E., Virudachalam S., Kuchibhotla J. Nuclear factor kappaB dominant negative genetic constructs inhibit X-ray induction of cell adhesion molecules in the vascular endothelium. Cancer Res. 58:(23):1998;5484-5488.
18. Hildebrandt G., et al. Mechanisms of the anti-inflammatory activity of low-dose radiation therapy. Int J Radiat Biol. 74:(3):1998;367-378.
19. Hong J.H., et al. Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys. 33:(3):1995;619-626.
20. Hong J.H., et al. Induction of c-fos and junB mRNA following in vivo brain irradiation. Brain Res Mol Brain Res. 48:(2):1997;223-228.
21. Imbert V., et al. Tyrosine phosphorylation of I kappa B-alpha activates NFkappa B without proteolytic degradation of I kappa B-alpha. Cell. 86:(5):1996;787-798.
22. Kanayama H.O. Demonstration that a human 26s proteolytic complex consists of a proteasome and multiple associated protein components and hydrolyzes ATP and ubiquitin-ligated proteins by closely linked mechanisms. Eur J Biochem. 206:(2):1992;567-578.
23. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 18:(49):1999;6867-6874.
24. Lawson B., Brewer J.W., Hendershot L.M. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway. J Cell Physiol. 174:(2):1998;170-178.
25. Lee D.H., Goldberg A.L. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem. 271:(44):1996;27280-27284.
26. Li N., Karin M. Ionizing radiation and short wavelength UV activate NFkappaB through two distinct mechanisms. Proc Nat Acad Sci USA. 95:(22):1998;13012-13017.
27. Limuro Y., et al. NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. J Clin Invest. 101:(4):1998;802-811.
28. Martin M., et al. Preferential induction of c-fos versus c-jun protooncogene during the immediate early response of pig skin to gamma-rays. Cancer Res. 53:(14):1993;3246-3249.
29. May M.J., Ghosh G. Signal transduction through NF-kappa B. Immunol Today. 19:(2):1998;80-88.
30. McBride W.H., Chiang C.S., Hong J.H., Withers H.R. Molecular and cellular responses of the brain to radiotherapy. Hortobagyi D.K.a.G. Current clinical topics in cancer chemotherapy. 1997;Blackwell Science Inc, Cambridge, MA.
31. Mohan N., Meltz M.L. Induction of nuclear factor kappa B after low-dose ionizing radiation involves a reactive oxygen intermediate signaling pathway. Radiat Res. 140:(1):1994;97-104.
32. Natarajan K., et al. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. Arch Biochem Biophys. 352:(1):1998;59-70.
33. Pahl H.L., Baeuerle P.A. The ER-overload response: activation of NFkappa B. Trends Biochem Sci. 22:(2):1997;63-67.
34. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18:(49):1999;6853-6866.
35. Pahl H.L., et al. Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention. J Cell Biol. 132:(4):1996;511-522.
36. Pajonk F., Pajonk K., McBride W. Apoptosis and radisensitization of Hodgkin's cells by proteasome inhibition. Int J Radiat Oncol Biol. 47:(4):2000;1025-1032.
37. Pajonk F., Pajonk K., McBride W.H. Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst. 91:(22):1999;1956-1960.
38. Prasad A.V., et al. Activation of nuclear factor kappa B in human lymphoblastoid cells by low-dose ionizing radiation. Radiat Res. 138:(3):1994;367-372.
39. Raju U., et al. IkappaBalpha degradation is not a requirement for the X-ray induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells. Int J Radiat Biol. 74:(5):1998;617-624.
40. Reinheckel T., et al. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J. 335:(Pt 3):1998;637-642.
41. Rolfe M., Chiu M.I., Pagano M. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med. 75:(1):1997;5-17.
42. Schreck R., Albermann K., Baeuerle P.A. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun. 17:(4):1992;221-237.
43. Sherman M.L., et al. Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci USA. 87:(15):1990;5663-5666.
44. Syljuasen R.G., Hong J.H., McBride W.H. Apoptosis and delayed expression of c-jun and c-fos after gamma irradiation of Jurkat T cells. Radiat Res. 146:(3):1996;276-282.
45. Trott K.R. Therapeutic effects of low radiation doses. Strahienther Onkol. 170:(1):1994;1-12.
46. Tsubuki S., Saito Y., Kawashima S. Purification and characterization of an endogenous inhibitor specific to the Z-Leu-Leu-Leu-MCA degrading activity in proteasome and its identification as heat-shock protein 90. FEBS Lett. 344:(2-3):1994;229-233.
47. Weichselbaum R.R., et al. Radiation induction of immediate early genes: effectors of the radiation-stress response. Int J Radiat Oncol Biol Phys. 30:(1):1994;229-234.
48. Williams F.H. The Roentgen rays in medicine and surgery as an aid in diagnosis and as a therapeutic agent; designed for the use of practitioners and students. 3rd ed. with enl. appendix. 1903;Macmillan & Co. Ltd, New York, London. xxxiii, 11. 757.
49. Wilson R.E., et al. Early response gene signalling cascades activated by ionising radiation in primary human B cells. Oncogene. 8:(12):1993;3229-3237.
50. Woloschak G.E., Felcher P., Chang-Liu C.M. Combined effects of ionizing radiation and cycloheximide on gene expression. Mol Carcinog. 13:(1):1995;44-49.